ADELAIDE, Australia & SAN DIEGO--(BUSINESS WIRE)--TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.
Axxora.com will become a distributor of TGR’s new ELISAONE™ technology assay reagents in the US and South America. ELISAONE™ immunoassay kits for cellular phosphoprotein detection are immediately available to purchase online from Axxora.com, with further additions to the portfolio coming soon.
“We’re thrilled to be expanding our distribution capabilities of ELISAONE™ through such a trusted and innovative resource as Axxora.com”, says Leanna Read, CEO and Managing Director of TGR BioSciences. “Axxora.com will provide an easy and efficient means for our clients to access our phosphoprotein portfolio content, and will help us grow our presence and revenues throughout the Americas. We feel our ELISAONE™ platform has several distinct practical advantages over current ELISAs, and will bring significant savings in assay time and expenditure for clients, while often yielding improved sensitivity”.
“We pride ourselves on offering uniquely innovative and high performing reagents from some of the World’s best specialist manufacturers”, says Brian Conkle, President at Axxora. “The ELISAONE™ phosphoprotein assays from TGR offer a unique combination of speed, sensitivity and flexibility for customers, and we expect these to be highly competitive with the more laborious ELISA market choices currently available”.
ELISAONE™ Cellular Phosphoprotein Assays
ELISAONE™ cell based immunoassays for phosphoprotein detection are geared towards researchers and cell biologists investigating G-protein coupled receptors and kinases, and cell signaling events in cancer, diabetes, inflammation and many other diseases. ELISAONE™ offers considerable time savings, is remarkably easy to perform and even allows investigators to measure multiple different analytes on a single plate. The assays can be run in as little as 1 hour, only require a single wash and provide an extremely sensitive means for quantitation of endogenously expressed phosphoproteins in cell lysates. Furthermore, there is no requirement for specialized instrumentation, with the assays using standard laboratory plate readers for signal detection.
Axxora.com is an innovative online marketplace for research reagents, with its US office located in San Diego, CA and several locations throughout Europe. Providing experienced customer care and technical support, Axxora.com offers access to over 50,000 products from 50 specialized original manufacturers of Life Science reagents from a single consolidated source. Axxora.com is a wholly owned subsidiary of Enzo Life Sciences.
About TGR BioSciences:
TGR BioSciences Pty Ltd (TGR) is a fast growing and innovative private biotechnology company based in Adelaide, South Australia, specializing in the development of drug discovery technologies and products to serve the global research and discovery markets for the Life Sciences. TGR provides the highest performing and sensitive cell based assays for analysis of GPCRs, kinases and cell signaling pathways to major pharmaceutical and biotechnology companies, and clients in government funded and academic laboratories worldwide. TGR already has on market a broad portfolio of state-of-the-art assays for cell-based screening used in high-throughput discovery and target identification of novel bioactives. TGR’s ELISAONE™ is a newly developed, fast and simple assay technology for the lower throughput research market, initially focused on phosphoprotein detection in cells, and available through distributors from early 2011. TGR is actively developing further novel cell based analysis technologies to advance research in areas such as oncology, neuroscience and other key therapeutic areas.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6669794&lang=en